BioSpace News Archive

Bloom Burton & Co. Inc. announces that, today, it and its affiliate acquired 1,453,070 common shares (Shares) and 6,636,734 compensation options (Compensation Options) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a short form prospectus dated May 9, 2023.

CANbridge Pharmaceuticals Inc. announced that data on a novel second-generation spinal muscular atrophy gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, was presented as a poster at the American Society of Gene and Cell Therapy 26th Annual Meeting, in Los Angeles.

Xbiotech Inc. announced that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest.

Acasti Pharma Inc. announced today that Prashant Kohli , CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023.

Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, and IAVI, an international nonprofit research organization focused on developing vaccines and antibodies against infectious and neglected diseases, today announced the signing of an agreement for end-to-end development of the tuberculosis (TB) vaccine candidate MTBVAC.

Kelonia Therapeutics today announced the results of preclinical research demonstrating that its in vivo Gene Placement System (iGPS™) technology efficiently delivered CAR molecules specifically to T cells at therapeutic dose levels in both mice and non-human primates (NHPs).

Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd., announced they will be operating under the new name Resolian — fully integrating the companies into one organization.

Plandai Biotechnology, Inc. announce the completion of a share exchange agreement whereby PLPL shall acquire one hundred percent of the issued and outstanding ByoPlanet Interests and ByoPlanet’s fixed tangible and intangible assets in exchange for all authorized, issued, and outstanding PLPL Preferred Common Shares and Common Stock.

Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.

Compare the Biomarket™, a groundbreaking clinical biosamples quotation platform, has officially launched today, promising researchers valuable insights into the clinical biosamples market and providing cost-effective solutions to accelerate scientific discovery. ™